DeCure for Cervical Mucinous Adenocarcinoma, Minimal Deviation Variant
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Cervical Mucinous Adenocarcinoma, Minimal Deviation Variant — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical Mucinous Adenocarcinoma, Minimal Deviation Variant maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical mucinous adenocarcinoma, minimal deviation variant is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serine/threonine kinase 11 (STK11) — STK11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8VSU · 2.86 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Minimal deviation carcinoma of the cervix is very rare, representing about 1% of adenocarcinomas of the cervix and less than one-sixth of well-differentiated cervical carcinomas. In a 1983 series of 13 cases, the two patients who died of cervical adenocarcinoma did so 6 and 14 years after initial diagnosis and treatment. That series reported better survival than earlier reports, but the cell types were more varied and the carcinomas were identified at early stages. An association with independent ovarian neoplasms was found. A 2021 case report states that patients with minimal deviation adenocarcinoma have a lower survival rate than patients with conventional human papillomavirus-related cervical adenocarcinoma.
A 2021 case report describes a 60-year-old woman with stage IB2 minimal deviation adenocarcinoma and lymph node metastasis. The report notes that surgical resection is the preferred and most effective treatment, but outcomes are often unsatisfactory. It states there is no therapeutic consensus, so each case must be treated individually. A 2011 case report describes a young woman with locally advanced minimal deviation adenocarcinoma who was successfully treated with concomitant chemoradiation followed by radical surgery, achieving a complete pathological response. The same report notes the intrinsic chemotherapy resistance and frequent failure of radiotherapy approaches that have raised the need to investigate multimodal strategies.
A 2021 case report of a 55-year-old postmenopausal woman diagnosed by biopsy describes minimal deviation adenocarcinoma as accounting for 1-3% of cervical adenocarcinoma. The 1983 report notes that minimal deviation carcinoma often grows slowly, and that the gross appearance of the cervix may be normal in early lesions. The 2021 case report emphasises a high rate of misdiagnosis and high aggressiveness, and that a precise preoperative pathologic diagnosis may reduce mortality due to missed optimal treatment with multiple surgical interventions.
What is still missing is a therapeutic consensus, as stated in the 2021 case report. No randomised trials exist for this rare variant. The evidence is limited to small case series and individual case reports, with no standardised chemotherapy or radiotherapy regimen established. Patient stratification by stage, lymph node status, and molecular markers is absent from the literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Gynecological Pathology · 1983 · 115 citations
Minimal Deviation Carcinoma (Adenoma Malignum) of the Cervix
AbstractMinimal deviation carcinoma of the cervix is very rare, representing about 1% of adenocarcinomas of the cervix and less than one-sixth of well-differentiated cervical carcinomas. Composed of distorted glands having an irregular outline and deeply positioned in the cervix, minimal deviation carcinoma often requires hysterectomy to produce a sufficiently deep margin to permit identification of invasion. The gross appearance of the cervix may be normal in early lesions. Minimal deviation carcinoma often grows slowly. The two patients who died of cervical adenocarcinoma did so 6 and 14 years after initial diagnosis and treatment. The 13 cases in this report differ from those previously reported in that the cell types were more varied (most cases in the literature are of a mucinous cell type), the carcinomas were identified at early stages, and the survival of patients was much better than in earlier reports. An association with independent ovarian neoplasms was found.
World Journal of Clinical Cases · 2021 · 3 citations · open access
Minimal deviation adenocarcinoma with elevated CA19-9: A case report
AbstractBACKGROUND: Minimal deviation adenocarcinoma is a rare malignancy with a high rate of misdiagnosis and high aggressiveness, and its diagnosis relies on histopathology. Surgical resection is the preferred and most effective treatment, but the outcomes are often unsatisfactory. CASE SUMMARY: A 60-year-old perimenopausal woman was admitted to the hospital and found to have elevated CA19-9 on physical examination without abdominal pain or vaginal bleeding. Clinical examination and positron emission tomography/computed tomography examination were unremarkable, magnetic resonance imaging examination was suggestive of dominant cervical lesions, and methylation examination was suggestive of malignant lesions. Tissue samples were taken from the suspected cervical lesion, and the final pathologic diagnosis was minimal deviation adenocarcinoma. Based on the pathologic diagnosis of suspected minimal deviation adenocarcinoma, radical abdominal total hysterectomy, bilateral oophorectomy, and pelvic and para-aortic lymph node dissection were performed. The final histological report confirmed minimal deviation adenocarcinoma of the cervix, stage IB2, with lymph node metastasis. Minimal deviation adenocarcinoma is a tumor with aggressive clinical behavior. CONCLUSION: Patients with minimal deviation adenocarcinoma have a lower survival rate than patients with conventional human papillomavirus-related cervical adenocarcinoma. A precise preoperative pathologic diagnosis may reduce the mortality rate due to missed optimal treatment with multiple surgical interventions. To date, there is no therapeutic consensus; therefore, each case must be treated individually.
Gynecologic and Obstetric Investigation · 2011 · 1 citations
A Complete Pathological Response to Treatment in a Young Patient with Locally Advanced Minimal DeviationAdenocarcinoma of the Uterine Cervix Undergoing Chemoradiation followed by Radical Surgery
AbstractMinimal deviation adenocarcinoma (MDA) is a very rare variant of cervical adenocarcinoma, this pathological entity is composed of mucinous very-well-differentiated glands deeply invading cervical stroma, and often surrounded by a desmoplastic reaction. Despite its benign histological appearance, MDA is typically characterized by aggressive clinical behavior and by relevant difficulties in achieving a final diagnosis. Moreover, the intrinsic chemotherapy resistance, as well as the frequent failure of radiotherapy approaches has raised the need to investigate the efficacy of multimodal strategies for the treatment of MDA patients. Here, we report a case of locally advanced MDA of the uterine cervix in a very young woman, who was successfully treated with concomitant chemoradiation followed by radical surgery.
GLOBAL JOURNAL FOR RESEARCH ANALYSIS · 2021 · 0 citations · open access
A RARE CASE OF MINIMAL DEVIATION ADENOCARCINOMA OF CERVIX – A CASE REPORT
AbstractMinimal deviation adenocarcinoma is a subtype of cervical adenocarcinoma and accounts for 1-3% of cervical adenocarcinoma . It is also known as adenoma malignum. We report a case of 55 year old postmenopausal women with complaints of low back pain, on examination cervix was replaced by indurated growth and was diagnosed as minimal deviation adenocarcinoma of cervix by biopsy
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
